PubMed Journals: Viruses

  Source:		PMID: 32106567

    		Viruses. 2020 Feb 25;12(3). pii: E254. doi:

			Preliminary Identification of Potential Vaccine
			Targets for the COVID-19 Coronavirus
			(SARS-CoV-2) Based on SARS-CoV
			Immunological Studies.

			Ahmed SF(1), Quadeer AA(1), McKay MR(1)(2).

			Author Information
			(1) Department of Electronic and Computer
			Engineering, The
			Hong Kong University of Science and Technology,
			Hong Kong, China.
			(2) Department of Chemical and Biological
			Engineering, The Hong Kong University of
			Science and Technology, Hong Kong, China.

			The beginning of 2020 has seen the
			emergence of COVID-19 outbreak caused by a
			novel coronavirus,
			Severe Acute Respiratory Syndrome
			Coronavirus 2 (SARS-CoV-2). There is an
			imminent need to better understand this new
			virus and to develop ways to control its spread.
			In this study, we sought to gain insights for
			vaccine design against SARS-CoV-2 by
			considering the high genetic similarity between
			SARS-CoV-2 and SARS-CoV, which caused
			the outbreak in 2003, and leveraging existing
			immunological studies of SARS-CoV. By
			screening the experimentally-determined
			SARS-CoV-derived B cell and T cell epitopes in
			the immunogenic structural proteins of
			SARS-CoV, we identified a set of B cell and T
			cell epitopes derived from the spike (S) and
			nucleocapsid (N) proteins that map identically
			to SARS-CoV-2 proteins. As no mutation has
			been observed in these identified epitopes
			among the 120 available SARS-CoV-2
			sequences (as of 21 February 2020), immune
			targeting of these epitopes may potentially offer
			protection against this novel virus. For the T cell
			epitopes, we performed a population coverage
			analysis of the associated MHC alleles and
			proposed a set of epitopes that is estimated to
			provide broad coverage globally, as well as in
			China. Our findings provide a screened set of
			epitopes that can help guide experimental
			efforts towards the development of vaccines
			against SARS-CoV-2.

			DOI: 10.3390/v12030254 PMID: 32106567

     			                         Tweet       Print